Treatment of allergic rhinitis (AR) is a complicated issue. Despite the availability of diagnostic and therapeutic recommendations (international and national), a wide range of existing therapy’s means and methods, good control of nasal symptoms, estimated by clinicians, is achieved in less than 1/2 (45%) of patients.
OBJECTIVE
To analyze clinical research data, related to the therapeutic efficacy of combined drug Ryaltris in AR, and comparison of them with the results, obtained in real-life clinical settings in Russia.
MATERIAL AND METHODS
The analysis of publications (articles and related abstracts), presented in PubMed database, was conducted. The choice of data was done according to the keywords: fixed combinations, olopatadine, mometasone furoate, allergic rhinitis.
RESULTS
On the one hand, faster onset of the clinical effect during the use of olopatadine hydrochloride, and on the another hand, more significant anti-inflammatory action of mometasone furoate determined the feasibility and potential benefits of double fixed combination of olopatadine hydrochloride and mometasone furoate in the nasal spray form for the AR treatment. A significant improvement of nasal symptoms’ assessment (TNSS, VAS — visual analog scale), high tolerability and safety of long-term (52 week) medicine administration during the use of olopatadine hydrochloride/mometasone furoate in the nasal spray form were shown in clinical trials and real-life clinical settings.
CONCLUSION
Ryaltris nasal spray demonstrates the benefits of intranasal antihistamine (rapid onset) and intranasal corticosteroid (lasting effect on main processes of allergic inflammation in the nasal mucosa), providing the effective control of AR symptoms not only in strict conditions of randomized clinical trials, but also in actual clinical practice in Russia. Effective and rapid symptomatic relief from the first day of therapy with optimum level of safety makes it the first-line medicine for the initial AR treatment.
